Works matching DE "DARUNAVIR"

Results: 425
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14

    Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.

    Published in:
    International Journal of STD & AIDS, 2012, v. 23, n. 7, p. 459, doi. 10.1258/ijsa.2012.011391
    By:
    • Bucciardini, R.;
    • D'Ettorre, G.;
    • Baroncelli, S.;
    • Ceccarelli, G.;
    • Parruti, G.;
    • Weimer, L. E.;
    • Fragola, V.;
    • Galluzzo, C. M.;
    • Pirillo, M. F.;
    • Lucattini, S.;
    • Bellagamba, R.;
    • Francisci, D.;
    • Ladisa, N.;
    • Antoni, A. Degli;
    • Guaraldi, G.;
    • Manconi, P. E.;
    • Vullo, V.;
    • Preziosi, R.;
    • Cirioni, O.;
    • Verucchi, G.
    Publication type:
    Article
    15
    16

    Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.

    Published in:
    2018
    By:
    • Stella-Ascariz, Natalia;
    • Montejano, Rocio;
    • Rodriguez-Centeno, Javier;
    • Alejos, Belen;
    • Schwimmer, Christine;
    • Bernardino, Jose I;
    • Rodes, Berta;
    • Allavena, Clotilde;
    • Hoffmann, Christian;
    • Gisslén, Magnus;
    • de Miguel, Rosa;
    • Esteban-Cantos, Andrés;
    • Wallet, Cédrick;
    • Raffi, François;
    • Arribas, Jose R;
    • NEAT 001/ ANRS 143 Study Group
    Publication type:
    journal article
    17
    18
    19
    20

    Polymorphic stability of darunavir and its formulation.

    Published in:
    Journal of Thermal Analysis & Calorimetry, 2016, v. 123, n. 3, p. 2185, doi. 10.1007/s10973-015-4984-3
    By:
    • Corrêa, Josilene;
    • Perissinato, Aline;
    • Reis Serra, Cristina;
    • Trevisan, Marcello;
    • Salgado, Hérida
    Publication type:
    Article
    21
    22

    Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir.

    Published in:
    Journal of Infection & Chemotherapy (Springer Science & Business Media B.V.), 2011, v. 17, n. 1, p. 105, doi. 10.1007/s10156-010-0082-4
    By:
    • Nakamura, Hitomi;
    • Miyazaki, Naoko;
    • Hosoya, Noriaki;
    • Koga, Michiko;
    • Odawara, Takashi;
    • Kikuchi, Tadashi;
    • Koibuchi, Tomohiko;
    • Kawana-Tachikawa, Ai;
    • Fujii, Takeshi;
    • Miura, Toshiyuki;
    • Iwamoto, Aikichi
    Publication type:
    Article
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35

    Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.

    Published in:
    HIV Medicine, 2015, v. 16, n. 5, p. 297, doi. 10.1111/hiv.12218
    By:
    • Vingerhoets, J;
    • Calvez, V;
    • Flandre, P;
    • Marcelin, A‐G;
    • Ceccherini‐Silberstein, F;
    • Perno, C‐F;
    • Mercedes Santoro, M;
    • Bateson, R;
    • Nelson, M;
    • Cozzi‐Lepri, A;
    • Grarup, J;
    • Lundgren, J;
    • Incardona, F;
    • Kaiser, R;
    • Sonnerborg, A;
    • Clotet, B;
    • Paredes, R;
    • Günthard, HF;
    • Ledergerber, B;
    • Hoogstoel, A
    Publication type:
    Article
    36
    37
    38
    39
    40
    41
    42

    Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

    Published in:
    HIV Medicine, 2013, v. 14, n. 1, p. 49, doi. 10.1111/j.1468-1293.2012.01060.x
    By:
    • Orkin, C;
    • DeJesus, E;
    • Khanlou, H;
    • Stoehr, A;
    • Supparatpinyo, K;
    • Lathouwers, E;
    • Lefebvre, E;
    • Opsomer, M;
    • Van de Casteele, T;
    • Tomaka, F
    Publication type:
    Article
    43

    Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 Substudy Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 Substudy

    Published in:
    HIV Medicine, 2012, v. 13, n. 8, p. 505, doi. 10.1111/j.1468-1293.2012.01004.x
    By:
    • Valantin, MA;
    • Kolta, S;
    • Flandre, P;
    • Algarte Genin, M;
    • Meynard, JL;
    • Ponscarme, D;
    • Slama, L;
    • Cuzin, L;
    • Kerviler, E;
    • Inaoui, R;
    • Katlama, C
    Publication type:
    Article
    44
    45
    46
    47
    48
    49
    50